{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:28:58Z","timestamp":1757701738657,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001661","name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oxygenated hemoglobin (OxyHem) in arterial blood may reflect disease severity in patients with systemic sclerosis (SSc). The aim of this study was to analyze the predictive value of OxyHem in SSc\u00a0patients screened for pulmonary hypertension (PH). OxyHem (g\/dl) was measured by multiplying the concentration of hemoglobin with fractional oxygen saturation in arterialized capillary blood. Prognostic power was compared with known prognostic parameters in SSc using uni- and multivariable analysis. A total of 280 SSc\u00a0patients were screened, 267 were included in the analysis. No signs of pulmonary vascular disease were found in 126 patients, while 141 patients presented with mean pulmonary arterial pressure\u2009\u2265\u200921\u00a0mmHg. Interstitial lung disease (ILD) was identified in 70 patients. Low OxyHem\u2009\u2264\u200912.5\u00a0g\/dl at baseline was significantly associated with worse survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.046). In the multivariable analysis presence of ILD, age\u2009\u2265\u200960\u00a0years and diffusion capacity for carbon monoxide (DLCO)\u2009\u2264\u200965% were negatively associated with survival. The combination of low DLCO and low OxyHem at baseline could predict PH at baseline (sensitivity 76.1%). This study detected for the first time OxyHem\u2009\u2264\u200912.5\u00a0g\/dl as a prognostic predictor in SSc\u00a0patients. Further studies are needed to confirm these results.<\/jats:p>","DOI":"10.1038\/s41598-023-28608-x","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T12:52:58Z","timestamp":1675255978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension"],"prefix":"10.1038","volume":"13","author":[{"given":"Panagiota","family":"Xanthouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ojan","family":"Gordjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska C.","family":"Trudzinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Egenlauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satenik","family":"Harutyunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicklas","family":"Milde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Gr\u00fcnig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Eichstaedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"28608_CR1","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","volume":"76","author":"M Elhai","year":"2017","unstructured":"Elhai, M. et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum Dis. 76, 1897\u20131905. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211448 (2017).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai, M., Meune, C., Avouac, J., Kahan, A. & Allanore, Y. Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 51, 1017\u20131026. https:\/\/doi.org\/10.1093\/rheumatology\/ker269 (2012).","journal-title":"Rheumatology (Oxford)"},{"key":"28608_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.reuma.2012.05.006","volume":"8","author":"E Toledano","year":"2012","unstructured":"Toledano, E. et al. A meta-analysis of mortality in rheumatic diseases. Reumatol. Clin. 8, 334\u2013341. https:\/\/doi.org\/10.1016\/j.reuma.2012.05.006 (2012).","journal-title":"Reumatol. Clin."},{"key":"28608_CR4","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","volume":"77","author":"W Wu","year":"2018","unstructured":"Wu, W. et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: The SPAR model. Ann. Rheum Dis. 77, 1326\u20131332. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213201 (2018).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/thx.2008.111393","volume":"64","author":"JJ Swigris","year":"2009","unstructured":"Swigris, J. J. et al. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax 64, 626\u2013630. https:\/\/doi.org\/10.1136\/thx.2008.111393 (2009).","journal-title":"Thorax"},{"key":"28608_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/rheumatology\/ket331","volume":"53","author":"G Ruiter","year":"2014","unstructured":"Ruiter, G. et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53, 285\u2013292. https:\/\/doi.org\/10.1093\/rheumatology\/ket331 (2014).","journal-title":"Rheumatology"},{"key":"28608_CR7","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1038\/s41598-020-67197-x","volume":"10","author":"FC Trudzinski","year":"2020","unstructured":"Trudzinski, F. C. et al. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. Sci. Rep. 10, 10544. https:\/\/doi.org\/10.1038\/s41598-020-67197-x (2020).","journal-title":"Sci. Rep."},{"key":"28608_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000513440","volume":"100","author":"CF Hinke","year":"2021","unstructured":"Hinke, C. F. et al. Prognostic value of oxygenated hemoglobin assessed during acute exacerbations of chronic pulmonary disease. Respiration 100, 387\u2013394. https:\/\/doi.org\/10.1159\/000513440 (2021).","journal-title":"Respiration"},{"key":"28608_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8, N. et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 37, 67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317 (2016).","journal-title":"Eur. Heart J."},{"key":"28608_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan, J. G. et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study. Ann. Rheum Dis. 73, 1340\u20131349. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203301 (2014).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR11","doi-asserted-by":"publisher","first-page":"824972","DOI":"10.1155\/2011\/824972","volume":"2011","author":"TW van Hal","year":"2011","unstructured":"van Hal, T. W., van Bon, L. & Radstake, T. R. A system out of breath: How hypoxia possibly contributes to the pathogenesis of systemic sclerosis. Int J Rheumatol 2011, 824972. https:\/\/doi.org\/10.1155\/2011\/824972 (2011).","journal-title":"Int J Rheumatol"},{"key":"28608_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","volume":"21","author":"MR Pokeerbux","year":"2019","unstructured":"Pokeerbux, M. R. et al. Survival and prognosis factors in systemic sclerosis: Data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res. Ther. 21, 86. https:\/\/doi.org\/10.1186\/s13075-019-1867-1 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"28608_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova, S. I. et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 66, 1625\u20131635. https:\/\/doi.org\/10.1002\/art.38390 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"28608_CR14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/ard.2010.144360","volume":"70","author":"J Fransen","year":"2011","unstructured":"Fransen, J. et al. Clinical prediction of 5-year survival in systemic sclerosis: Validation of a simple prognostic model in EUSTAR centres. Ann. Rheum Dis. 70, 1788\u20131792. https:\/\/doi.org\/10.1136\/ard.2010.144360 (2011).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","volume":"17","author":"S Panopoulos","year":"2018","unstructured":"Panopoulos, S. et al. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun. Rev. 17, 816\u2013820. https:\/\/doi.org\/10.1016\/j.autrev.2018.02.008 (2018).","journal-title":"Autoimmun. Rev."},{"key":"28608_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini, G. et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index. Ann. Rheum Dis. 76, 270\u2013276. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209768 (2017).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3899\/jrheum.180018","volume":"46","author":"VM Hsu","year":"2019","unstructured":"Hsu, V. M. et al. Risk factors for mortality and cardiopulmonary hospitalization in systemic sclerosis patients at risk for pulmonary hypertension, in the PHAROS registry. J. Rheumatol. 46, 176\u2013183. https:\/\/doi.org\/10.3899\/jrheum.180018 (2019).","journal-title":"J. Rheumatol."},{"key":"28608_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00408-017-0034-1","volume":"195","author":"A Gadre","year":"2017","unstructured":"Gadre, A. et al. Six-minute walk test as a predictor of diagnosis, disease severity, and clinical outcomes in Scleroderma-associated pulmonary hypertension: The DIBOSA study. Lung 195, 529\u2013536. https:\/\/doi.org\/10.1007\/s00408-017-0034-1 (2017).","journal-title":"Lung"},{"key":"28608_CR19","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1183\/09031936.00134506","volume":"29","author":"MM Hoeper","year":"2007","unstructured":"Hoeper, M. M., Pletz, M. W., Golpon, H. & Welte, T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 29, 944\u2013950. https:\/\/doi.org\/10.1183\/09031936.00134506 (2007).","journal-title":"Eur. Respir. J."},{"key":"28608_CR20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04066-2020","author":"S Valentin","year":"2021","unstructured":"Valentin, S. et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.04066-2020 (2021).","journal-title":"Eur. Respir. J."},{"key":"28608_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.semarthrit.2008.06.002","volume":"39","author":"FF Al-Dhaher","year":"2010","unstructured":"Al-Dhaher, F. F., Pope, J. E. & Ouimet, J. M. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin. Arthritis Rheum 39, 269\u2013277. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.06.002 (2010).","journal-title":"Semin. Arthritis Rheum"},{"key":"28608_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","volume":"78","author":"ER Volkmann","year":"2019","unstructured":"Volkmann, E. R. et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann. Rheum Dis. 78, 122\u2013130. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213708 (2019).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0140-6736(65)90286-2","volume":"2","author":"JH Langlands","year":"1965","unstructured":"Langlands, J. H. & Wallace, W. F. Small blood-samples from ear-lobe puncture: A substitute for arterial puncture. Lancet 2, 315\u2013317. https:\/\/doi.org\/10.1016\/s0140-6736(65)90286-2 (1965).","journal-title":"Lancet"},{"key":"28608_CR24","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy, E. C. & Medsger, T. A. Jr. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573\u20131576 (2001).","journal-title":"J. Rheumatol."},{"key":"28608_CR25","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65, 2737\u20132747. https:\/\/doi.org\/10.1002\/art.38098 (2013).","journal-title":"Arthritis Rheum"},{"key":"28608_CR26","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","volume":"79","author":"P Xanthouli","year":"2020","unstructured":"Xanthouli, P. et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: The impact of the new definition of pulmonary arterial hypertension. Ann. Rheum Dis. 79, 370\u2013378. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216476 (2020).","journal-title":"Ann. Rheum Dis."},{"key":"28608_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/thx.39.11.818","volume":"39","author":"GH Guyatt","year":"1984","unstructured":"Guyatt, G. H. et al. Effect of encouragement on walking test performance. Thorax 39, 818\u2013822 (1984).","journal-title":"Thorax"},{"key":"28608_CR28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NS Goh","year":"2008","unstructured":"Goh, N. S. et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am. J. Respir. Crit. Care Med. 177, 1248\u20131254. https:\/\/doi.org\/10.1164\/rccm.200706-877OC (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"28608_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","author":"M Humbert","year":"2022","unstructured":"Humbert, M. et al. ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237 (2022).","journal-title":"Eur. Heart J."},{"key":"28608_CR30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01914-2018","author":"SD Nathan","year":"2018","unstructured":"Nathan, S. D. et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01914-2018 (2018).","journal-title":"Eur. Respir. J."},{"key":"28608_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/acr.22121","volume":"66","author":"L Chung","year":"2014","unstructured":"Chung, L. et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: Outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res. (Hoboken) 66, 489\u2013495. https:\/\/doi.org\/10.1002\/acr.22121 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28608-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28608-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T07:02:51Z","timestamp":1675580571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28608-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28608"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28608-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"28 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PX has received personal fees from MSD and OMT, outside the submitted work. OG, NBe, FT and NM have nothing to declare. CAE received speaking fees from MSD, outside the submitted work. BE received travel fees, consulting fees, speaking fees, and\/or honoraria from Actelion, MSD, Bayer and OMT (less than $10,000 each). SH has received personal fees from Bayer, MSD, Actelion and GSK, outside the submitted work. AMM has received personal fees from Bayer, MSD and Boehringer-Ingelheim outside the submitted work. CN has received consulting fees, speaking fees, and\/or honoraria from Actelion, MSD, Boehringer, Novartis, Bayer, and AstraZeneca (less than $10,000 each). NBl has received consulting fees, speaker fees, and\/or honoraria from AbbVie, BMS, Pfizer, Roche, Novartis, UCB, Janssen-Cilag, Novartis, SOBI, Actelion outside the submitted work. HML has received consulting fees, speaking fees, and\/or honoraria from AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, and Thermo Fisher. EG has received grants and personal fees from Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics; and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House (less than $10,000 each).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1839"}}